LSA
ALXN

L & S Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

L & S Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9,476
Closed -$1.02M – 316
2019
Q4 		$1.02M Sell
9,476
-6,665
-41% -$713K 0.13% 148
2019
Q3 		$1.58M Sell
16,141
-13,544
-46% -$1.53M 0.22% 124
2019
Q2 		$3.89M Sell
29,685
-3,196
-10% -$412K 0.51% 53
2019
Q1 		$4.45M Buy
32,881
+25,388
+339% +$3.16M 0.6% 49
2018
Q4 		$730K Buy
+7,493
New +$886K 0.14% 149

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

L & S Advisors's ALXN Position: Q1 2020 in Review

L & S Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 9,476 shares — an estimated $1.02M sold.

L & S Advisors first reported a position in ALXN in Q4 2018 and held it in 5 quarters. The position peaked at $4.45M in Q1 2019. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • L & S Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • L & S Advisors sold 9,476 Alexion Pharmaceuticals shares in Q1 2020, an estimated $1.02M.
  • L & S Advisors first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 5 quarters.
  • L & S Advisors's Alexion Pharmaceuticals position peaked at $4.45M in Q1 2019.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on L & S Advisors's 13F filing for Q1 2020, filed 13 May 2020.